Non-promotional infographic

Patient support

Resources and downloadable booklets created to help you support your patients who have been prescribed Zejula.

Patient resources

For your patients already on Zejula, we offer a homecare service

Zejula Homecare Service

GSK and HealthNet offer a 3-part homecare service to help you monitor your patients throughout their treatment.

Icon for blood monitoring
Icon for blood pressure measurement
Icon for Zejula delivery Icon for blood monitoring
Icon for blood pressure measurement
Icon for Zejula delivery

Want to discover more about how we can support you and your patients?

ZEJULA is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinumsensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Footnotes

MoA, mechanism of action; QoL, quality of life.

References

  1. ZEJULA Summary of Product Characteristics.

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store.

Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

March 2022 | PM-GB-NRP-WCNT-210024 (V1.0)